Download - Antihistamine Toxicity
-
8/2/2019 Antihistamine Toxicity
1/27
DR MOHD ZAWAWI ABU BAKAR
KK NABAWAN
KURSUS PSR PKK KENINGAU
12/4/2012
-
8/2/2019 Antihistamine Toxicity
2/27
Class of antihistamine
Human Histamine receptors- H1, H2, H3, H4
Clinical use : H1 and H2
H3 & H4 : under research H1 receptor antagonists- 1st generation sedating
antihistamine & 2nd generation non sedating antihistamine
H2 receptor antagonists- cimetidine, ranitidine, famotidine
-
8/2/2019 Antihistamine Toxicity
3/27
-
8/2/2019 Antihistamine Toxicity
4/27
-
8/2/2019 Antihistamine Toxicity
5/27
Morbidity & Mortality
Of all antihistamine exposures reported toUS poison control centers in 2007 (NPDSdata),2817 (3.6%) resulted in moderate-to-major toxicityand 69 (0.090%)
resulted in fatality. The vast majority offatalities were associated withdiphenhydramine.
-
8/2/2019 Antihistamine Toxicity
6/27
Morbidity & Mortality
First-generation H1-receptor antagonists, suchas diphenhydramine, may be particularly
dangerous because they may cause pronouncedagitation and seizures, resulting occasionally inrhabdomyolysis and acidosis. Also, a quinidinelikesodium channel blocking effect, and at high doses,
a potassium channel blocking effect (HERG1K),may cause delayed conduction (prolongedQRS) and repolarization (prolonged QT) andcontribute to ventricular dysrhythmias.
-
8/2/2019 Antihistamine Toxicity
7/27
Morbidity & Mortality
Second-generation H1-receptor antagonists,such as terfenadine and astemizole (now removedfrom the US market), may result in QT intervalprolongation and life-threatening
polymorphic ventricular tachycardia (torsadede pointes),particularly when combined witherythromycin.
-
8/2/2019 Antihistamine Toxicity
8/27
Morbidity & Mortality
From 1990-2005 the Civil Aerospace MedicalInstitute (CAMI) reported thatantihistamines were found in 338 of 5383pilot fatalities. It was felt that
antihistamines were a factor in or the causeof 50 and 13 cases, respectively. Theprevalence ofantihistamine use amongfatal crashes increased from 4% to 11%
over this time span, indicating a worrisometrend.Reports of delayed pulmonary edema from
antihistamine overdose have been reported.
-
8/2/2019 Antihistamine Toxicity
9/27
Morbidity & Mortality
Famotidine has been shown to cause a significantincrease in serum phosphate levels amonghemodialysis patients taking calcium carbonate(even at the recommended dose of 10 mg/d).
In severely ill patients, an administration ofintravenous cimetidine can result in bradycardiaand hypotension that can progress to cardiacarrest.
USFDA reported serious adverse eventsincluding 7 deaths & 22 cases of respiratorydepression assoc. with promethazine usage inchildren < 2 yrs (not directly related to wt baseddosing).
-
8/2/2019 Antihistamine Toxicity
10/27
Antihistamine usage-age
According to the 2007American Association of PoisonControl Centers' National Poison Data System(NPDS) data,
the greatest number of toxic antihistamine exposuresis associated with patients younger than 6 years(35,550 or 44%), though the relationship between ingesteddose and severity of symptoms has been shown in oneretrospective review to be insignificant.
The 2007 NPDS data also indicate that antihistamines werethe 10th most frequently reported exposure amongchildren younger than 5 years.
A positive association between depression symptomsamong elderly persons (>65 y) and H2 blocker use has been
reported. Inappropriate use of antihistamines for URI symptoms andotitis media may unnecessarily expose children to thepotential side effects of this class of medication.Furthermore, no study has shown a benefit in themanagement of these conditions with eitherantihistamines or decongestants.
-
8/2/2019 Antihistamine Toxicity
11/27
Structural classes of H1 antihistamine
1. Alkylamines (eg, brompheniramine, chlorpheniramine,dexchlorpheniramine, pheniramine, triprolidine)
2. Ethanolamines (eg, carbinoxamine, clemastine,dimenhydrinate, diphenhydramine, doxylamine)
3. Ethylenediamines (eg, pyrilamine, tripelennamine)
4. Phenothiazines (eg, methdilazine, promethazine,trimeprazine)
5. Piperidines (eg, cyproheptadine, fexofenadine,loratadine), terfenadine and astemizole have been
recalled from the US market6. Piperazines (eg, cetirizine, cyclizine, hydroxyzine,levocetirizine, meclizine)
-
8/2/2019 Antihistamine Toxicity
12/27
Alkylamines derivatives
eg. chlorpheniramine, dexchlorpheniramine,triprolidine.
Among most potent antihistamine Produce more CNS stim. & less drowsiness
Chlorpheniramine suppress visuospatial cognition& visuomotor coordination-may cause fall
-
8/2/2019 Antihistamine Toxicity
13/27
Ethanolamine derivatives
Eg, diphenhydramine, dimenhydrinate
Strong atropine-like activity, drowsiness common
Diphenhydramine assoc. with prolongation ofQT(not shown to cause Torsades de pointes)
Massive ingestion seizures and cardiacconduction delays
Doxylamine can cause rhabdomyolysis & renalfailure
-
8/2/2019 Antihistamine Toxicity
14/27
Ethylenediamine derivatives
Eg. Antazoline(eye drops), oxymetazoline(nasaldrops)
Weak CNS effects
Ppt angle closure glaucoma Interacts with monoamine oxidase inh.
hypertensive crisis
Tripelennamine(US) exposure-myoclonic jerk,
hallucination, agitation
Tripelennamine + pentazocine(weak opiod) =heroin-like effects
-
8/2/2019 Antihistamine Toxicity
15/27
Phenothiazine derivatives
Eg. Promethazine
Strong anticholinergic activity
Akathisia & dystonic reaction are common similar structure to CPZ, haloperidol
Promethazine can cause fatal resp.
depression/apnea in children< 2 yrs
-
8/2/2019 Antihistamine Toxicity
16/27
Piperidine derivatives
Eg. Loratidine, desloratidine, fexofenadine
Selectively binds H1 receptor & low bindingaffinity for cholinergic & alfa adrenergic receptor
Long half life- up to 24 hrs
Terfenadine-recalled fr market(1992) dt assoc. withtorsade de pointes both in acute overdose andtherapeutic dose
Prolonged QT syndrome & cardiac arrythmiasrarely assoc. with loratidine
-
8/2/2019 Antihistamine Toxicity
17/27
Piperazines derivatives
eg, cetirizine,levocetirizine,
Similar pharmacokinetic property to piperidine
Cetirizine & levocetirizine-non sedative Hydroxyzine & meclizine-sedative
No reported cardiac events
-
8/2/2019 Antihistamine Toxicity
18/27
-
8/2/2019 Antihistamine Toxicity
19/27
Anticholinergic S/E
Peripheral dry mouth, blurring of vision, flushed skin,less sweating, dilated pupils, lossaccommodation,intestinal ileus, urinary retention
Central CNS- disorientation, agitation, delirium, short
term memory impairment, incoherent speech, meaninglessmotor activity(eg. repetitive picking) & visualhallucination-*(psychosis usu. Assoc. with AH, paranoia &intact sensorium)
Seizures, esp. in epilepsy and acute poisoning Others-somnolence, lethargy, EPS, anxiety
Chronic abuse(Benadryl)- withdrawal Sx with restlessness,irritability,excessive blinking(no EPS+psychosis)
-
8/2/2019 Antihistamine Toxicity
20/27
CVS S/E
Commonest Sinus tachycardia, rarely, vent.
Tachycardia, torsade de pointes, hypotension(highdose)
Antihistamine w anticholinergic effects slowscardiac Na channels & decrease cardiac conduction
& myocardial contractility(pump failure inoverdose)- diphenhydramine, chlorpheniramine &certain phenothiazine
VT 4X more in non sedating antihistamine
Prolonged QT-diphenhydramine,phenothiazine,piperidine(loratidine)
Torsades de pointes- only in piperidine, esp.terfenadine & astemizole.
-
8/2/2019 Antihistamine Toxicity
21/27
Resp. S/E
Resp. depression and apnea esp. withphenothiazine(promethazine)
High risk group- peads< 2yrs, not directly related
to wt based dosing Pulmonary congestion secondary to cardiogenic
shock & ventricular failure-most common indiphenhydramine toxicity
-
8/2/2019 Antihistamine Toxicity
22/27
Skin-fixed drug eruption(rare)-cetirizine Musculoskeletal-rhabdomyolysis in high dose of
doxylamine
Renal failure- secondary to doxylamine inducedrhabdomyolysis
-
8/2/2019 Antihistamine Toxicity
23/27
H2 receptor antagonist
Selective H2 receptor inhibitor
Not blocking H1 receptor & dont have
antimuscarinic activity Common S/E : GI(diarrhea, vomiting), dizziness,
somnolence, headache, arthralgia, rash
Rare S/E: A.pancreatitis, brady, AV block,confusion, depression, hallucination, blooddisorder, gyneacomastia, impotence
-
8/2/2019 Antihistamine Toxicity
24/27
Drugs interaction
Antihistamine enhances other antimuscarinic &sedative such as TCA, hypnotics, anxiolytics,MOAI
Co-admin. Of antifungal imidazole(eg.Ketoconazole,itraconazole) & macrolide ab.Increases plasma concentration of 2nd gen.antihistamine
Grapefruit ingestion increases plasmaconcentration of terfenadine
Alcohol intake increases antihistamine sedative
effects
-
8/2/2019 Antihistamine Toxicity
25/27
Caution & contraindication
High risk groups
1. Children( esp < 2yrs)- resp. depression
2. Elderly-fall, CNS,CVS
3. Renal dis.- adjusted dose
4. Liver dis.- sedative antihist. Contraindicated insevere liver dis.
5. Asthma, COPD, Chronic lung dis.
6. BPH & urinary retention7. Acute glaucoma
8. Pyloric outflow obstruction
9. Epilepsy
-
8/2/2019 Antihistamine Toxicity
26/27
Pregnancy & lactation
-1
st
gen. antihistamine- no evidence ofteratogenicity(cat B)
-2nd gen. antihist-limited data on safety profile(cat C)
-H2 receptor antagonist- ranitidine, cimetidine,
famotidine not known to be harmful(cat. B)
-
8/2/2019 Antihistamine Toxicity
27/27
References
BNF 58, September 2009
http://emedicine.medscape.com/article/812828-overview
http://www.patient.co.uk/doctor/Antihistamines.htm
I.Matok et al. Safety of H2 Blockers Use During Pregnancy, J Clin.Pharmacol., Jan. 2010;50(1) :81-87
http://emedicine.medscape.com/article/812828-overviewhttp://www.patient.co.uk/doctor/Antihistamines.htmhttp://www.patient.co.uk/doctor/Antihistamines.htmhttp://emedicine.medscape.com/article/812828-overviewhttp://emedicine.medscape.com/article/812828-overviewhttp://emedicine.medscape.com/article/812828-overview